Brandon Capital Partners (AU)

https://www.brandoncapital.com.au

LinkedIn: https://www.linkedin.com/company/brandon-capital

Brandon Capital is Australasia’s leading life science venture capital firm, with an international presence and team members across the US and UK. From early-stage seed investment through to expansion capital, Brandon Capital supports life science companies from proof-of-concept through to commercialisation. Our venture model is unique: we don’t just provide investment, we partner with inventors, entrepreneurs and research organisations, providing hands-on support and expertise to increase their chance of success. Brandon BioCatalyst, Brandon Capital’s Australasian-based collaboration, brings together 50 trans-Tasman medical research institutes, investors, and governments all united in progressing the next generation of medical therapies and technology. Brandon BioCatalyst supports the development and commercialisation of early-stage biomedical discoveries associated with member research organisations, providing both capital and expertise to guide the successful development of new therapies. *

	Start	2007-01-01 established
	Industry	investment management
	Industry 2	LIFE SCIENCES
	Person	Thompson, Stephen (Brandon Capital 202011 formerly at Apax Partners)
	Person 2	Tobin, Jonathan (Brandon Capital 202209 Partner before Arix Bioscience 201706)

	Region	Melbourne VIC
	Country	Australia
	Street	31 Queen Street Level 9
	City	3000 Melbourne VIC
		Address record changed: 2024-06-08

Basic data	Employees	n. a.
	Currency	AUD
	Annual sales	800,000,000 (funds, managed (2019) 2019-12-18)

		* Document for »About Section«: Catalym GmbH. (11/22/22). "Press Release: Catalym Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors". Oxford.

		Record changed: 2024-07-14